Major Depressive Disorder Clinical Trial
Official title:
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Therapy
Verified date | April 2019 |
Source | Alkermes, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
Status | Completed |
Enrollment | 142 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Diagnosed with a major depressive episode (MDE) - Body mass index less than or equal to 40 kg/m2 - Have been treated with an adequate dose of SSRI/SNRI during the current MDE for at least 8 weeks, with the same, adequate dose over the last 4 weeks that is expected to remain stable throughout the study - History of inadequate response during the entire current MDE to 1 or 2 adequate antidepressant treatments, including current treatment - Be otherwise physically healthy Exclusion Criteria: - Have an axis I diagnosis of delirium, dementia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder, obsessive-compulsive disorder, panic disorder, acute stress disorder, or posttraumatic stress disorder - Have a clinically significant current axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder - Are experiencing hallucinations, delusions, or any psychotic symptomatology in the current MDE - Receive new onset psychotherapy within 6 weeks of screening - Use of opioid agonists (eg, codeine, oxycodone, morphine) within 14 days before screening - Have received electroconvulsive therapy during the current MDE - Have attempted suicide within the past 2 years - Have a thyroid pathology - Have a history of a seizure disorder or of neuroleptic malignant syndrome/serotonin syndrome - Have a positive test for human immunodeficiency virus (HIV) Additional inclusion/exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
United States | Alkermes Investigational Site | Atlanta | Georgia |
United States | Alkermes Investigational Site | Austin | Texas |
United States | Alkermes Investigational Site | Baltimore | Maryland |
United States | Alkermes Investigational Site | Bellevue | Washington |
United States | Alkermes Investigational Site | Berlin | New Jersey |
United States | Alkermes Investigational Site | Boston | Massachusetts |
United States | Alkermes Investigational Site | Brooklyn | New York |
United States | Alkermes Investigational Site | Canton | Ohio |
United States | Alkermes Investigational Site | Charleston | South Carolina |
United States | Alkermes Investigational Site | Dallas | Texas |
United States | Alkermes Investigational Site | Dayton | Ohio |
United States | Alkermes Investigational Site | Fort Myers | Florida |
United States | Alkermes Investigational Site | Haverhill | Massachusetts |
United States | Alkermes Investigational Site | Hoffman Estates | Illinois |
United States | Alkermes Investigational Site | Houston | Texas |
United States | Alkermes Investigational Site | Lauderhill | Florida |
United States | Alkermes Investigational Site | Leesburg | Florida |
United States | Alkermes Investigational Site | New York | New York |
United States | Alkermes Investigational Site | North Miami | Florida |
United States | Alkermes Investigational Site | Oceanside | California |
United States | Alkermes Investigational Site | Oklahoma City | Oklahoma |
United States | Alkermes Investigational Site | Philadelphia | Pennsylvania |
United States | Alkermes Investigational Site | Saint Petersburg | Florida |
United States | Alkermes Investigational Site | San Antonio | Texas |
United States | Alkermes Investigational Site | Santa Ana | California |
United States | Alkermes Investigational Site | Torrance | California |
United States | Alkermes Investigational Site | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Alkermes, Inc. |
United States,
Fava M, Memisoglu A, Thase ME, Bodkin JA, Trivedi MH, de Somer M, Du Y, Leigh-Pemberton R, DiPetrillo L, Silverman B, Ehrich E. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomiz — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline to Week 4 in Hamilton Rating Scale for Depression (HAM-D17) Total Score | The HAM-D17 scale is a clinician-administered questionnaire comprised of 17 items used to measure the severity of MDD symptoms. Scores range from 0 (no apparent symptoms) to 50 (most severe symptoms). Individual questionnaire items include depressed mood, work and activities, insomnia (early), insomnia (middle), insomnia (late), genital symptoms, somatic symptoms (gastrointestinal), loss of weight, somatic symptoms (general), feelings of guilt, suicide, anxiety (psychic), anxiety (somatic), hypochondriasis, insight, agitation, and retardation. | Baseline and 4 weeks for each stage | |
Secondary | Proportion of Patients Who Exhibited Treatment Response (HAM-D17) | The proportion of subjects demonstrating HAM-D17 treatment response, defined as a = 50% reduction in HAM-D17 score from baseline to the end of the efficacy period (Week 4). The HAM-D17 is a clinician administered questionnaire comprised of 17 questions used to assess the severity of a patient's depression. Scores range from 0 (no apparent symptoms) to 50 (most severe symptoms). Individual questionnaire items include depressed mood, work and activities, insomnia (early), insomnia (middle), insomnia (late), genital symptoms, somatic symptoms (gastrointestinal), loss of weight, somatic symptoms (general), feelings of guilt, suicide, anxiety (psychic), anxiety (somatic), hypochondriasis, insight, agitation, and retardation. | 4 weeks for each stage | |
Secondary | Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score | The MADRS-10 scale is a clinician-administered questionnaire comprised of 10 items used to measure the severity of MDD symptoms. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms). Individual questionnaire items include: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts. | 4 weeks for each stage | |
Secondary | Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score | The CGI-S is a 7-point scale that requires the clinician to assess how mentally ill the patient is at a specific point in time. Based on the scale, patients are categorized as follows: "1: normal, not at all ill"; "2: borderline mentally ill"; "3: mildly ill"; "4: moderately ill"; "5: markedly ill"; "6: severely ill"; and "7: among the most extremely ill patients." | 4 weeks for each stage |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |